BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced the results of regulatory actions regarding REVLIMID® in Australia in multiple myeloma (MM), and in Canada and the European Union in deletion 5q myelodysplastic syndromes (MDS).
